ReviewClinical microbiology reviews2004
DNA vaccines against human immunodeficiency virus type 1 in the past decade.
Review in Clinical microbiology reviews, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 92 citations in OpenAlex.
- DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.Clinical and vaccine immunology : CVI · 2012Trial
- Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy.Clinical and vaccine immunology : CVI · 2008Trial
- Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites.Infection and immunity · 2005Trial
- Review
- Evolution of drug delivery systems: From 1950 to 2020 and beyond.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity.Human vaccines & immunotherapeutics · 2017Review
- Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination.Vaccine · 2016Article
- Article
- Role of interleukin-2 and herpes simplex virus 1 in central nervous system demyelination in mice.Journal of virology · 2013Article
- Plasmodium inui infection reduces the efficacy of a simian immunodeficiency virus DNA vaccine in a rhesus macaque model through alteration of the vaccine-induced immune response.The Journal of infectious diseases · 2012Article
- Microbicides: a new hope for HIV prevention.The Indian journal of medical research · 2011Review
- Use of cytokine immunotherapy to block CNS demyelination induced by a recombinant HSV-1 expressing IL-2.Gene therapy · 2011Article
- Macrophage IL-12p70 signaling prevents HSV-1-induced CNS autoimmunity triggered by autoaggressive CD4+ Tregs.Investigative ophthalmology & visual science · 2011Article
- Multivalent immunity targeting tumor-associated antigens by intra-lymph node DNA-prime, peptide-boost vaccination.Cancer gene therapy · 2011Article
- Current progress in the development of a prophylactic vaccine for HIV-1.Drug design, development and therapy · 2010Review
- Highly active antiretroviral therapy potently suppresses HIV infection in humanized Rag2-/-gammac-/- mice.AIDS research and human retroviruses · 2010Article
- A novel recombinant bacterial vaccine strain expressing dual viral antigens induces multiple immune responses to the Gag and gp120 proteins of HIV-1 in immunized mice.Antiviral research · 2008Article
- Vaccination of rhesus macaques with a vif-deleted simian immunodeficiency virus proviral DNA vaccine.Virology · 2008Article
- Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses.Vaccine · 2008Article
- Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon.Journal of virology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article reviews advances in the field of human immunodeficiency virus type 1 (HIV-1) and AIDS vaccine development over the last decade, with an emphasis on the DNA vaccination approach. Despite the discovery of HIV-1 and AIDS in humans nearly 20 years ago, there is no vaccine yet that can prevent HIV-1 infection. The focus has shifted toward developing vaccines that can control virus replication and disease progression by eliciting broadly cross-reactive T-cell responses. Among several approaches evaluated, the DNA-based modality has shown considerable promise in terms of its ability to elicit cellular immune responses in primate studies. Of great importance are efforts aimed at improvement of the potency of this modality in the clinic. The review discusses principles of DNA vaccine design and the various mechanisms of plasmid-encoded antigen presentation. The review also outlines current DNA-based vaccine strategies and vectors that have successfully been shown to control virus replication and slow disease progression in animal models. Finally, it lists recent strategies that have been developed as well as novel approaches under consideration to enhance the immunogenicity of plasmid-encoded HIV-1 antigen in various animal models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.